SUN PHARMACEUTICAL INDUSTRIES LTD.

Sun Pharmaceutical Industries Limited announced that its drug LEQSELVI® (deuruxolitinib) demonstrated sustained efficacy and safety over two years in severe alopecia areata (AA) patients. Data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 showed a consistent safety profile with generally mild to moderate adverse events, and no deaths, thrombosis, or major cardiovascular events reported at the FDA-approved dose. Long-term efficacy analyses indicated durable scalp hair regrowth, with a high percentage of patients maintaining response. These findings reinforce LEQSELVI®'s potential as a long-term treatment option for severe AA.

Sun Pharmaceutical Industries Limited has submitted its ESG Overview for the financial year 2025-26. The report, prepared with reference to GRI Standards 2021 and externally assured by DNV Business Assurance India Private Limited, covers 44 manufacturing and R&D locations, representing 84% of operational sites for EHS indicators and 100% for other indicators. The overview details the company's performance and initiatives across environmental, social, and governance aspects, including corporate governance, ethics, risk management, product quality, energy management, emissions, waste, water management, and stakeholder engagement. Sun Pharma, a global specialty generic pharmaceutical leader with USD 6.6 billion in revenues, operates across approximately 100 countries.

Sun Pharmaceutical Industries Limited has announced a global licensing, commercialization, and manufacturing agreement for lerodalcibep, a PCSK9 inhibitor, with LIB Therapeutics. The agreement grants Sun Pharma exclusive rights outside the United States and China. Lerodalcibep, branded as Lyrokaul in the EU, received EU approval on September 21, 2026, for hypercholesterolemia and mixed dyslipidemia. This deal significantly strengthens Sun Pharma's Innovative Medicines portfolio, tapping into a substantial PCSK9 market ex-US and China, projected to reach US$3.7 billion and growing at 38% CAGR. LIB Therapeutics will receive upfront and milestone payments, plus royalties. Lerodalcibep offers once-monthly dosing, ambient storage, and addresses a significant unmet need in cardiovascular care by helping patients achieve LDL-C goals.

Sun Pharmaceutical Industries Ltd announced that its shareholders have approved the reclassification of certain individuals from the 'Promoter Group' category to the 'Public' category. This decision, made in accordance with Regulation 31A of the SEBI Listing Regulations, follows previous intimations to the stock exchanges. The change will be reflected in the company's subsequent quarterly shareholding patterns. The company secretary and compliance officer, Anoop Deshpande, confirmed the approval.

Sun Pharmaceutical Industries Ltd has announced the closure of its trading window for dealing in the company's shares. This closure will be effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Financial Results for the quarter and half-year ended September 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated separately. This measure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading.

Sun Pharmaceutical Industries Limited's subsidiaries, including Sun Pharmaceutical Industries, Inc., Taro Pharmaceutical Industries Ltd., and Taro Pharmaceuticals U.S.A., Inc., have entered into a settlement agreement with a plaintiff in the In re Generic Pharmaceuticals Pricing Antitrust Litigation. The settlement, for a confidential amount, resolves all claims asserted against the subsidiaries in the U.S. Eastern District of Pennsylvania. The agreement includes a full release of claims and is made without any admission of wrongdoing. Other terms of the settlement remain confidential.

Sun Pharmaceutical Industries Ltd has announced the incorporation of 'Sun Pharma Global Treasury Centre IFSC Limited' as an indirect wholly owned subsidiary. This new entity, established in the International Financial Services Centre (IFSC) at GIFT City, Gandhinagar, Gujarat, will function as the Global Treasury Centre for the Sun Pharma Group. Its primary objectives include managing treasury, funding, liquidity, and cash management activities. The subsidiary has been incorporated with an initial equity share capital subscription of approximately ₹9.50 Crore in cash. As it is newly incorporated, it has not yet commenced operations and has no turnover.

Sun Pharmaceutical Industries Limited participated in a White House ceremony, announcing agreements with the U.S. government to enhance access to affordable medicines. As part of the commitment, Sun Pharma will extend Most Favored Nation (MFN) pricing to state Medicaid programs and for future innovative medicine launches. The agreement also acknowledges Sun Pharma's U.S. investments by delaying Section 232 tariffs on innovative pharmaceutical products for over two years. The U.S. is a critical market for Sun Pharma, representing approximately 27% of its global revenue and a cornerstone of its growth strategy, further evidenced by its recent acquisition of Organon & Co.

Sun Pharmaceutical Industries Limited and its subsidiaries have received a favorable outcome in the Lipitor antitrust litigation in the United States. The United States Court of Appeals for the Third Circuit affirmed the District Court's decision, granting summary judgment in favor of Sun Pharma and denying class certification to the plaintiffs. This ruling significantly concludes the litigation, which alleged that a patent settlement agreement unlawfully delayed generic competition for Lipitor (Atorvastatin).

Sun Pharmaceutical Industries Ltd has received no-objection letters from both the National Stock Exchange of India (NSE) and BSE Limited (BSE) for the reclassification of certain individuals from the 'Promoter Group' to the 'Public' category. This reclassification is in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously intimated about this process on May 14, 22, and 26, 2026. The individuals whose status is being reclassified include Krishna Vrundavandas Valia, Sudhir Vrundavandas Valia, and Raksha Sudhir Valia. Sun Pharma is required to ensure compliance with subsequent disclosure requirements related to this reclassification.